Ligandal Company
Ligandal presented its approach for rapid vaccine prototyping on its website, stating that its synthetic scaffold can additionally serve as a targeting ligand mimicking viral entry to target diseased cells and tissues with therapeutic agents. These “mini viral scaffolds can be synthesized in hours, and rapidly scaled to 100kg+ scale to meet global needs.
Unlike recombinant and other approaches, Ligandal said, its vaccine approach needs to use fewer than 70 amino acids out of an approximately 1,200 amino acid spike protein in order to generate a predicted trifunctional scaffold for ACE2 binding and TCR/antibody recognition.
Connections from
Founded Date:
N/A
Headquarters:
United States
Technology:
COVID
Employee Number:
N/A
Industry:
Vaccine/Drug
Number Of Exists:
N/A
Funding Status:
N/A
Investor Type:
N/A
Investment Stage:
N/A